Zobrazeno 1 - 10
of 149
pro vyhledávání: '"microbiome therapeutics"'
Autor:
Jason Goldsmith, Sarah Tomkovich, John G. Auniņš, Barbara H. McGovern, Jennifer C. Mahoney, Brooke R. Hasson, Christopher W J McChalicher, David S. Ege
Publikováno v:
Gut Microbes, Vol 16, Iss 1 (2024)
Advances in microbiome therapeutics have been motivated by a deeper understanding of the role that the gastrointestinal microbiome plays in human health and disease. The FDA approval of two stool-derived live biotherapeutic products (LBPs), REBYOTA®
Externí odkaz:
https://doaj.org/article/d50c2aaf0d6047ffbd335412cd5b848c
Autor:
Colleen S. Kraft, Matthew Sims, Michael Silverman, Thomas J. Louie, Paul Feuerstadt, Edward S. Huang, Sahil Khanna, Charles S. Berenson, Elaine E. L. Wang, Stuart H. Cohen, Louis Korman, Christine Lee, Colleen R. Kelly, Alberto Odio, Paul P. Cook, Bret Lashner, Mayur Ramesh, Princy Kumar, Ananya De, Asli Memisoglu, David A. Lombardi, Brooke R. Hasson, Barbara H. McGovern, Lisa von Moltke, Darrell S. Pardi, on behalf of the ECOSPOR III and ECOSPOR IV investigators
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 10, Pp 2105-2121 (2024)
Abstract Introduction Recurrent Clostridioides difficile infection (rCDI) often occurs after standard-of-care antibiotics. VOWST oral spores (VOS, previously SER-109), an FDA-approved orally administered microbiome therapeutic, is indicated to preven
Externí odkaz:
https://doaj.org/article/ba87c7a699914c4c8d06cf93ba025fb8
Publikováno v:
Pharmacological Research, Vol 207, Iss , Pp 107321- (2024)
The critical role of the gut microbiome in gastrointestinal cancers is becoming increasingly clear. Imbalances in the gut microbial community, referred to as dysbiosis, are linked to increased risks for various forms of gastrointestinal cancers. Path
Externí odkaz:
https://doaj.org/article/ca8e8a2bac704537a2a040062222c1a5
Publikováno v:
Frontiers in Microbiomes, Vol 3 (2024)
The recent FDA approvals of Rebyota™ and Vowst™ represent landmark milestones within the burgeoning field of live microbiota-based products. Future microbiota-based treatment approaches also hold significant promise for treating patients with a m
Externí odkaz:
https://doaj.org/article/218c2837c9674db7af6e92283bb20be2
Publikováno v:
Cells, Vol 13, Iss 23, p 2003 (2024)
Although global life expectancy has increased over the past 20 years due to advancements in managing infectious diseases, one-fifth of people still die from infections. In response to this ongoing threat, significant efforts are underway to develop v
Externí odkaz:
https://doaj.org/article/98943d06d4454b7ba455668ff446386e
Autor:
Rebecca Kerstens, Paul Joyce
Publikováno v:
Biomedicines, Vol 12, Iss 8, p 1738 (2024)
Parkinson’s Disease is the second most prevalent neurological disorder globally, and its cause is still largely unknown. Likewise, there is no cure, and existing treatments do little more than subdue symptoms before becoming ineffective. It is incr
Externí odkaz:
https://doaj.org/article/67593a24322b4b40a247bdf6ff00da2c
Autor:
Oana-Alina Petrariu, Ilda Czobor Barbu, Adelina-Gabriela Niculescu, Marian Constantin, Georgiana Alexandra Grigore, Roxana-Elena Cristian, Grigore Mihaescu, Corneliu Ovidiu Vrancianu
Publikováno v:
Frontiers in Microbiology, Vol 14 (2024)
The imbalance of microbial composition and diversity in favor of pathogenic microorganisms combined with a loss of beneficial gut microbiota taxa results from factors such as age, diet, antimicrobial administration for different infections, other und
Externí odkaz:
https://doaj.org/article/da87780807724a97bec01a4c2b05966d
Autor:
Fabienne Kurt, Gabriel E. Leventhal, Marianne Rebecca Spalinger, Laura Anthamatten, Philipp Rogalla von Bieberstein, Carmen Menzi, Markus Reichlin, Marco Meola, Florian Rosenthal, Gerhard Rogler, Christophe Lacroix, Tomas de Wouters
Publikováno v:
Gut Microbes, Vol 15, Iss 1 (2023)
ABSTRACTThe success of fecal microbiota transplants (FMT) has provided the necessary proof-of-concept for microbiome therapeutics. Yet, feces-based therapies have many associated risks and uncertainties, and hence defined microbial consortia that mod
Externí odkaz:
https://doaj.org/article/90151f7cd74f4bf8aed4068ee8ff03a9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 12 (2022)
Externí odkaz:
https://doaj.org/article/4b78609a98044711bac4e1f724088d87